Shoulder Innovations reports Q1 EPS (41c), consensus (43c)

Reports Q1 revenue $16.71M, consensus $14.53M. “We are very pleased with our first quarter performance, which reflects accelerating revenue growth and intensifying commercial momentum across our entire organization,” said Rob Ball, CEO of Shoulder Innovations (SI). “Net revenue growth of 65%, implant volume growth of 51%, and continued improvement in gross margin demonstrate the strength and efficiency of our rapidly expanding ecosystem.” Ball continued, “Building on this traction, recent product portfolio milestones, including the full commercial launch of our InSet I-135RFX Humeral Stem, meaningfully extend the comprehensive suite of solutions we offer surgeons and their patients. This disciplined financial and operational execution to start the year provides us with increased confidence in the trajectory of the business and enables us to increase our full year 2026 revenue guidance.”